Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC

Boothbay Fund Management LLC increased its position in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 1,916.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 228,297 shares of the company’s stock after purchasing an additional 216,976 shares during the period. Boothbay Fund Management LLC owned 1.26% of Avalo Therapeutics worth $2,902,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AVTX. Orbimed Advisors LLC increased its position in Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock worth $17,150,000 after buying an additional 382,300 shares during the period. Nantahala Capital Management LLC boosted its holdings in shares of Avalo Therapeutics by 10.6% in the second quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company’s stock valued at $4,965,000 after acquiring an additional 95,000 shares during the period. Caligan Partners LP purchased a new position in shares of Avalo Therapeutics during the third quarter worth approximately $10,592,000. Balyasny Asset Management L.P. purchased a new position in shares of Avalo Therapeutics during the third quarter worth approximately $10,390,000. Finally, Vanguard Group Inc. increased its holdings in shares of Avalo Therapeutics by 314.9% in the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock valued at $8,803,000 after acquiring an additional 525,696 shares during the period. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $16.02 on Tuesday. The stock has a market capitalization of $296.53 million, a P/E ratio of -2.99 and a beta of 0.84. The company’s fifty day moving average is $15.89 and its two-hundred day moving average is $15.61. Avalo Therapeutics, Inc. has a 1 year low of $3.39 and a 1 year high of $20.72.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, January 15th. Guggenheim assumed coverage on shares of Avalo Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $50.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a research note on Friday, January 9th. Finally, Mizuho raised Avalo Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.